Xu Wang
- Molecular Biology top 10%
- Cancer Research top 5%
- Oncology top 10%
- Biomedical Engineering top 10%
- Biomaterials top 5%
- Topics
- RNA modifications and cancer (8 papers)Cancer-related Molecular Pathways (7 papers)Nanoplatforms for cancer theranostics (7 papers)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Xu Wang
115 papers receiving 2.3k citations
Peers
Comparison fields: 5 of 140
- Molecular Biology 1.0k
- Cancer Research 356
- Oncology 343
- Biomedical Engineering 304
- Biomaterials 195
Countries citing papers authored by Xu Wang
This map shows the geographic impact of Xu Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xu Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xu Wang more than expected).
Fields of papers citing papers by Xu Wang
This network shows the impact of papers produced by Xu Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xu Wang. The network helps show where Xu Wang may publish in the future.
Co-authorship network of co-authors of Xu Wang
This figure shows the co-authorship network connecting the top 25 collaborators of Xu Wang. A scholar is included among the top collaborators of Xu Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xu Wang. Xu Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 2 | |
| 5 | 3 | |
| 6 | 5 | |
| 7 | 2 | |
| 8 | 6 | |
| 9 | 1 | |
| 10 | 5 | |
| 11 | 28 | |
| 12 | 2 | |
| 13 | 18 | |
| 14 | 20 | |
| 15 | 20 | |
| 16 | 57 | |
| 17 | 141 | |
| 18 | 74 | |
| 19 | 150 | |
| 20 | Impacts of Folic Acid,Riboflavin Deficiency and MTHFR A1298C Polymorphism on Human Lymphocytes Genomic Stability | 1 |
About Xu Wang
Xu Wang is a scholar working on Periodontics, Oncology and Cancer Research, having authored 122 papers that have together received 2.3k indexed citations. Recurring topics across this work include RNA modifications and cancer (8 papers), Cancer-related Molecular Pathways (7 papers) and Nanoplatforms for cancer theranostics (7 papers). The work is most often cited by research in Cancer Research (356 citations), Molecular Biology (1.0k citations) and Biomaterials (195 citations). Xu Wang has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Wantao Chen, Ming Yan, Qin Xu, Jianjun Zhang, Wei Cao, Xing Qin, Juan Ni, Tong Ji, Wantao Chen and Yun Guo. Their work appears in journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.